Navigation Links
HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
Date:9/28/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 28, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that clinical data for the HeartWare® Ventricular Assist System will be presented on Sunday, October 2, 2011 at the 25th EACTS Annual Meeting in Lisbon, Portugal.

A presentation by Mark S. Slaughter, M.D., entitled HeartWare®: Results of the ADVANCE Bridge to Transplant Trial, is scheduled for Sunday, October 2, 2011, at noon local time (7:00 a.m. U.S. Eastern Daylight Time) in Auditorium 1 of the Lisbon Congress Centre.  Dr. Slaughter, a principal investigator for HeartWare's ADVANCE trial, is Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville.  The presentation will include clinical data from ADVANCE, as well as from the Continued Access Protocol for that study.

Investor Breakout Session and Webcast

Following the data presentation at EACTS, HeartWare management will host an investor breakout session with Dr. Slaughter, which will be available via audio webcast and conference call, at 2:00 p.m. local time (9:00 a.m. U.S. Eastern Daylight Time) on October 2, 2011 in Room 1.06 of the Lisbon Congress Centre.  

The audio from the meeting will be available to the public via webcast through the Company's website at (http://www.heartware.com/) by selecting "EACTS Investor Meeting" under the section titled "Corporate Presentations" on the home page.  A replay of the audio webcast will be available through the above weblink shortly following completion of the investor meeting. The audio for the meeting may also be accessed by dialing 1-800-215-2410 five minutes prior to the scheduled start time and referencing passcode 46162598.  For callers outside the United States, please dial +1-617-597-5410 and reference passcode 46162598.

Slides from the presentation at EACTS will be available following the presentation on the Company's International website (http://www.heartware.com) by selecting the International region, then Clinicians, then Clinical Trials.  

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol and is not yet commercially available.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
2. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
3. HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
4. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
5. HeartWare to Report Financial Results for Second Quarter of 2011
6. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
7. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
8. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
9. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
10. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
11. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... fiscal year ended December 31, 2016. ... This news release should ... and management discussion and analysis for the years ended December ... and are available at www.sedar.com and on the ...
(Date:2/22/2017)... Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... 2016 investor conference call and webcast at 8:30 a.m., Eastern ... will cover an update on Merrimack,s recent progress as well ... financial results. A press release detailing the information to be ... Wednesday, March 1. Investors and the general public are invited ...
(Date:2/22/2017)... 2017 Summary Provides understanding and ... and agreements entered into by the worlds leading healthcare ... Description The Global Non-Small Cell Lung Cancer Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... ANGLESTRONG , the new recovery management app with ... App Store and Google Play . Florida-based Sober Network, Inc., the ... industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is a ...
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a ... derive a heart-protective benefit from eating soy foods, while others do not, a University ... are able to produce equol—a substance made by some types of “good” gut bacteria ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading global ... management, today announced that Keppel Corporation has selected Apptricity Travel and Expense Management ... “We are excited to announce the partnership between Keppel and Apptricity for our ...
Breaking Medicine News(10 mins):